Skip to main content
. 2014 Aug 4;9(8):e104068. doi: 10.1371/journal.pone.0104068

Figure 6. Prognostic impact of treatments in DLBCL risk-stratified according to immunohistochemical subgroups.

Figure 6

(A, B) OS (A) and PFS (B) of all patients treated with CHOP or R-CHOP. (C, D) OS (C) and PFS (D) of patients treated with CHOP or R-CHOP in GCB subgroup. (E, F) OS (E) and PFS (F) of patients treated with CHOP or R-CHOP in non-GCB subgroup. OS, overall survival; PFS, progression-free survival; GCB, germinal center B-cell.